Want to see IN:EPIGRAL full AI Analyst Report?
Top Page
Epigral Ltd
(EPIGRAL)
Select Model
Select Model
Rating:62Neutral
Price Target:
₹1,234.00
▲(6.10% Upside)
Action:Reiterated
Date:07/22/26
The score is driven primarily by solid profitability and a notably strengthened balance sheet, offset by weak and volatile cash generation (negative latest free cash flow and mixed cash conversion). Technical indicators are neutral-to-mixed (positive vs short-term averages but below the 200-day with negative MACD), while valuation appears reasonable with a low dividend yield.
Positive Factors
Stronger balance sheet and low leverage
Leverage reduced to ~0.26x and expanded equity materially improve financial flexibility and solvency. This durable balance-sheet repair lowers refinancing and distress risk, preserves room for capex or opportunistic M&A, and supports stability through chemical-cycle volatility over months.
Negative Factors
Weak free cash flow and cash conversion
Negative latest-year free cash flow and mixed cash conversion are structural concerns: they limit internal funding for capex, working-capital cushions, and dividends. Persistent FCF weakness signals earnings may not translate to liquidity, constraining strategy and increasing reliance on external financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Stronger balance sheet and low leverage
Leverage reduced to ~0.26x and expanded equity materially improve financial flexibility and solvency. This durable balance-sheet repair lowers refinancing and distress risk, preserves room for capex or opportunistic M&A, and supports stability through chemical-cycle volatility over months.
Read all positive factors
Epigral Ltd (EPIGRAL) vs. iShares MSCI India ETF (INDA)
Market Cap
₹51.95B
Dividend Yield0.4%
Average Volume (3M)6.15K
Price to Earnings (P/E)19.7
Beta (1Y)1.29
Revenue Growth4.81%
EPS Growth-37.93%
CountryIN
Employees1,135
SectorGeneral
Sector StrengthN/A
IndustryChemicals
Share Statistics
EPS (TTM)62.82
Shares Outstanding43,141,340
10 Day Avg. Volume5,951
30 Day Avg. Volume6,147
Financial Highlights & Ratios
PEG Ratio-1.15
Price to Book (P/B)1.57
Price to Sales (P/S)1.40
P/FCF Ratio-535.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)62.1
Revenue Forecast (FY)₹27.01B
Epigral Ltd Business Overview & Revenue Model
Company Description
Epigral Limited operates in the chemical sector, focusing on the production and global distribution of chlor-alkali products and their associated derivatives. Its diverse product range encompasses chlorinated polyvinyl chloride (CPVC) resins, epic...
How the Company Makes Money
null...
Epigral Ltd Financial Statement Overview
Summary
Income Statement
70
Positive
Balance Sheet
78
Positive
Cash Flow
45
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 26.26B | 24.95B | 25.50B | 18.94B | 21.69B | 15.50B |
| Gross Profit | 7.74B | 4.63B | 10.67B | 7.79B | 6.43B | 7.48B |
| EBITDA | 5.88B | 5.50B | 7.11B | 4.77B | 6.81B | 5.01B |
| Net Income | 2.71B | 3.32B | 3.58B | 1.96B | 3.53B | 2.53B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 35.05B | 31.52B | 27.94B | 24.32B | 21.24B |
| Cash, Cash Equivalents and Short-Term Investments | 50.20M | 54.60M | 965.00M | 31.83M | 142.40M | 250.85M |
| Total Debt | 0.00 | 5.72B | 5.93B | 9.64B | 8.79B | 9.93B |
| Total Liabilities | -22.21B | 12.84B | 12.48B | 15.40B | 13.63B | 13.98B |
| Stockholders Equity | 22.21B | 22.21B | 19.05B | 12.54B | 10.69B | 7.26B |
Cash Flow | ||||||
| Free Cash Flow | 316.30M | -65.30M | 2.46B | -7.90M | 2.10B | -1.72B |
| Operating Cash Flow | 2.67B | 3.88B | 4.41B | 3.98B | 6.26B | 2.84B |
| Investing Cash Flow | -1.73B | -3.55B | -2.62B | -4.01B | -4.37B | -4.55B |
| Financing Cash Flow | -980.80M | -457.90M | -1.64B | -75.98M | -2.00B | 1.95B |
Epigral Ltd Technical Analysis
Positive
1163.05
Price Trends
1109.19
Positive
1151.18
Positive
1145.56
Positive
Market Momentum
33.21
Negative
63.40
Neutral
82.25
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:EPIGRAL, the sentiment is Positive. The current price of 1163.05 is above the 20-day moving average (MA) of 1147.06, above the 50-day MA of 1109.19, and above the 200-day MA of 1145.56, indicating a bullish trend. The MACD of 33.21 indicates Negative momentum. The RSI at 63.40 is Neutral, neither overbought nor oversold. The STOCH value of 82.25 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:EPIGRAL.
Epigral Ltd Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | ₹8.79B | 10.85 | ― | 0.38% | 13.23% | 21.18% | |
62 Neutral | ₹51.95B | 19.73 | ― | 0.43% | 4.81% | -37.93% | |
57 Neutral | ₹51.61B | 78.90 | ― | 2.25% | 7.07% | ― | |
56 Neutral | ₹8.13B | 14.87 | ― | ― | 1.41% | 946.38% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | ₹35.34B | 12.97 | ― | 3.08% | 8.62% | 20.79% | |
54 Neutral | ₹238.50B | 31.04 | ― | 0.45% | 8.20% | 29.06% |
* General Sector Average
IN:EPIGRAL
Epigral Ltd
1,227.55
-561.73
-31.39%
IN:DEEPAKNTR
Deepak Nitrite Limited
1,733.65
-21.53
-1.23%
IN:GUJALKALI
Gujarat Alkalies & Chemicals Ltd.
714.25
135.17
23.34%
IN:INDOAMIN
Indo Amines Limited
122.80
-23.84
-16.26%
IN:STYRENIX
Styrenix Performance Materials Ltd
1,986.40
-620.95
-23.82%
IN:VALIANTORG
Valiant Organics Limited
304.55
-35.45
-10.43%
Epigral Ltd Corporate Events
Epigral Denies Role in Surge in Trading Volumes, Cites Market-Driven Factors
Jul 22, 2026
Epigral Ltd has responded to a query from the National Stock Exchange after a significant increase in trading volumes of its shares across exchanges. The company stated that it has already made all required disclosures relating to its operations a...
Exchange Seeks Clarification From Epigral After Trading Surge
Jul 21, 2026
The exchange has reported a significant increase in trading volumes for Epigral Ltd shares and has intervened to ensure investors have access to the most up to date information. In response to this unusual market activity, the exchange has formall...
Epigral Creates Wholly-Owned Chemical Subsidiary to Bolster Manufacturing Reach
Jul 7, 2026
Epigral Limited has incorporated a new wholly-owned subsidiary, Epigral Advanced Materials Limited, in India to expand its manufacturing footprint in chemicals. The unit, set up with a paid-up capital of Rs 1,00,000 and fully owned by Epigral, is ...
Epigral holds 19th AGM via virtual platform, to publish voting results by June 10
Jun 8, 2026
Epigral Limited held its 19th Annual General Meeting on June 8, 2026, conducted entirely via video conferencing and other audio-visual means in line with the Companies Act and SEBI’s listing regulations. The meeting, chaired by Chairman and ...
Epigral Schedules Investor Video Meeting with Spark Capital Advisors
May 12, 2026
Epigral Limited has scheduled a one-on-one video conference meeting with Spark Capital Advisors (India) Pvt. Ltd. on 15 May 2026, as disclosed under Regulation 30 of SEBI’s Listing Obligations and Disclosure Requirements. The company notes t...
Epigral to Hold One-on-One Virtual Meet With Systematix Group on 8 May
May 6, 2026
Epigral Ltd has notified the exchanges that it will hold a one-on-one virtual meeting with institutional investor Systematix Group on 8 May 2026 via video conferencing, with the schedule subject to change based on exigencies of either party. The c...
Epigral Publishes FY26 Audited Results in Multiple Newspapers
May 4, 2026
Epigral Ltd has notified the stock exchanges that it has published its audited financial results for the fourth quarter and full year ended 31 March 2026 in multiple newspaper editions. The disclosure, made in line with SEBI’s listing and di...
Epigral posts Q4 FY26 earnings call audio for investor access
May 3, 2026
Epigral Limited has notified the National Stock Exchange of India and BSE Limited that an audio recording of its conference call discussing the financial results for the fourth quarter of fiscal year 2026 has been made available online. The disclo...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.